# Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting®…

- Source: PR Newswire M&A
- Published: 2026-11-08T19:11:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/novo-post-hoc-analysis-finds-wegovy-2-4-mg-was-associated-with-improvements-in-liver-markers-in-adults-with-mash-with-liver-scarring-and-a-bmi-less-than-27-kgm2--presented-at-the-liver-meeting-aasld-2026--302932759.html
- Canonical: https://groundlevelnews.com/story/novo-post-hoc-analysis-finds-wegovy-2-4-mg-was-associated-with-improve-0452c3/

A post hoc analysis of adults with MASH and liver scarring with a BMI below 27 kg/m² found that measures of liver injury, fibrosis, and disease activity improved at week 72 among participants receiving semaglutide 2.4 mg once weekly injection versus placebo Non-invasive fibrosis...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._